Mannan Haider, Palavras Marly Amorim, Claudino Angelica, Hay Phillipa Jane
Translational Health Research Institute, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Eating Disorders Program (PROATA), Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), Rua Major Maragliano 241, São Paulo 04017, SP, Brazil.
Nutrients. 2025 Apr 7;17(7):1288. doi: 10.3390/nu17071288.
: To inform person-centred clinical practice, it is important to know what features may predict or moderate treatment outcomes. Thus, we investigated pre-treatment clinical features and mid-therapy reduction in loss of control over eating (MTLOCE), including impacts on treatment outcomes of a new manualised psychotherapy, a healthy approach to weight management and food in eating disorders (HAPIFED). HAPIFED was developed as an integrated psychological and behavioural treatment for individuals with bulimia nervosa or binge eating disorder, which are co-morbid with a high body mass index (BMI). : In total, 50 participants were randomised to HAPIFED and 48 were randomised to the control cognitive behaviour therapy-enhanced group. Assessments included mental health-related quality of life (MHRQoL), eating disorder symptom severity, binge-eating frequency, BMI, and loss of control over eating (LOCE) at baseline, mid-treatment, end-treatment, and 6 and 12 months end of follow-up (EndFU). These were measured with the SF-12, the EDE-Q, and the LOCES, respectively. Linear and negative binomial mixed models were used. Missing data were imputed multiple times, assuming intention of treatment for the analysis. : Pre-treatment eating disorder symptom severity, MHRQoL, and BMI positively predicted eating disorder symptom severity, MHRQoL, and BMI up to 6 and 12 months end of follow-up. Mid-treatment LOCE MTLOCE predicted improved MHRQoL (coefficient = 0.387, 95% CI 0.0824-0.6921, = 0.004), reduced binge-eating frequency (IRR = 0.5637, 95% CI 0.3539-0.8977, = 0.0191), and eating disorder symptom severity (coefficient= -0.65, 95% CI -1.0792--0.2217, = 0.0139). Neither purging nor illness duration were a significant predictor of any of the outcomes. The effect of HAPIFED was not moderated by baseline weight/BMI but was moderated negatively by MTLOCE for binge-eating frequency (coefficient = -0.636, SE = 0.28, < 0.05, IRR = 0.529) and eating disorder symptom severity (coefficient = -0.268, SE = 0.13, < 0.05, Cohen's d = -0.102). : Greater control over eating improved MHRQoL and decreased the frequency of binge-eating episodes and eating disorder symptom severity. These positive effects were moderated by being in the HAPIFED group, supporting previous findings of benefits to people's mental health through participation in the HAPIFED trial.
为指导以患者为中心的临床实践,了解哪些特征可能预测或调节治疗结果非常重要。因此,我们调查了治疗前的临床特征以及治疗中期饮食失控减少情况(MTLOCE),包括一种新的手册化心理治疗、饮食失调中健康的体重管理和饮食方法(HAPIFED)对治疗结果的影响。HAPIFED是作为一种针对神经性贪食症或暴饮暴食症且伴有高体重指数(BMI)的个体的综合心理和行为治疗方法而开发的。
总共50名参与者被随机分配到HAPIFED组,48名被随机分配到对照认知行为疗法强化组。评估包括心理健康相关生活质量(MHRQoL)、饮食失调症状严重程度、暴饮暴食频率、BMI以及在基线、治疗中期、治疗结束时以及随访结束(EndFU)6个月和12个月时的饮食失控(LOCE)。这些分别用SF - 12、EDE - Q和LOCES进行测量。使用了线性和负二项混合模型。假设分析采用治疗意向,对缺失数据进行多次插补。
治疗前的饮食失调症状严重程度、MHRQoL和BMI可正向预测直至随访结束6个月和12个月时的饮食失调症状严重程度、MHRQoL和BMI。治疗中期的LOCE(MTLOCE)可预测MHRQoL改善(系数 = 0.387,95%置信区间0.0824 - 0.6921,P = 0.004)、暴饮暴食频率降低(发病率比 = 0.5637,95%置信区间0.3539 - 0.8977,P = 0.0191)以及饮食失调症状严重程度降低(系数 = -0.65,95%置信区间 - 1.0792 - - 0.2217,P = 0.0139)。催吐和病程均不是任何结果的显著预测因素。HAPIFED的效果不受基线体重/BMI的调节,但MTLOCE对暴饮暴食频率(系数 = -0.636,标准误 = 0.28,P < 0.05,发病率比 = 0.529)和饮食失调症状严重程度(系数 = -0.268,标准误 = 0.13,P < 0.05,科恩d值 = -0.102)有负向调节作用。
对饮食的更好控制改善了MHRQoL,降低了暴饮暴食发作频率和饮食失调症状严重程度。这些积极效果在HAPIFED组中得到调节,支持了之前通过参与HAPIFED试验对人们心理健康有益的研究结果。